The indications for neoadjuvant therapy are expanding; currently, most of high-risk patients (staged at T ≥ 2 or N > 1) and patients with tumors > 2 cm in size with distinct biological features (HER-2 positive or triple negative breast cancer) receive neoadjuvant therapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.